Welcome to LookChem.com Sign In|Join Free

CAS

  • or

53648-55-8

Post Buying Request

53648-55-8 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

53648-55-8 Usage

Description

Dezocine is an injectable mixed-agonist/antagonist analgesic, indicated for the management of pain when an opioid analgesic is suitable. It is characterized by its high affinity for both mu and delta receptors, and low effect on kappa receptors. Dezocine is known for its rapid onset of action, short half-life, low abuse potential, and minimal side effects.

Uses

Used in Pain Management:
Dezocine is used as an opioid analgesic for the relief of post-operative pain, with its potency being comparable to Meperidine. It is particularly effective due to its unique receptor binding profile, which contributes to its low abuse potential and reduced side effects compared to other opioids.
Used in Pharmaceutical Industry:
Dezocine is utilized in the development of analgesic medications, offering an alternative to traditional opioid analgesics. Its distinct pharmacological properties make it a valuable component in the treatment of moderate to severe pain, while minimizing the risk of dependence and adverse effects associated with other opioid类药物.

Originator

Wyeth-Ayerst (American Home Products) (U.S.A.)

Biological Functions

Dezocine (Dalgan) is a synthetic aminotetralin derivative with potent agonist–antagonist effects.The onset of activity and potency as an analgesic are comparable to those of morphine. Although the drug requires glucuronidation during metabolism, patients with hepatic insufficiency clear it normally.The main route for clearance is the kidney.Thus, patients with renal dysfunction are prone to buildup of dezocine over time. As an antagonist, dezocine is more potent than pentazocine. As an agonist, dezocine produces analgesia and respiratory depression (which is readily reversed by naloxone), but unlike pentazocine, it has little if any effect on the cardiovascular system. Dezocine is indicated as an analgesic for moderate to severe pain. In addition, it shows promise in chronic pain states, such as with victims of severe burns. Contraindications and adverse effects of the drug are similar to those described for morphine. No tendency toward abuse has been demonstrated thus far.

Mechanism of action

Dezocine is classified as a mixed agonist/antagonist. The SAR of dezocine is unique among the opioids. It is a primary amine, whereas all other nonpeptide opioids are tertiary amines. Its exact receptor selectivity profile has not been reported; however, its pharmacology is most similar to that of buprenorphine. It seems to be a partial agonist at μ receptors, to have little effect at κ receptors, and to exert some agonist effect at δ receptors.

Clinical Use

It is useful for the treatment of moderate to severe pain. It is available for intramuscular and intravenous dose. The drug is indicated for postoperative and cancerinduced pain.

Check Digit Verification of cas no

The CAS Registry Mumber 53648-55-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,6,4 and 8 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 53648-55:
(7*5)+(6*3)+(5*6)+(4*4)+(3*8)+(2*5)+(1*5)=138
138 % 10 = 8
So 53648-55-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15+,16+/m1/s1

53648-55-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name dezocine

1.2 Other means of identification

Product number -
Other names Dezocine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:53648-55-8 SDS

53648-55-8Downstream Products

53648-55-8Relevant articles and documents

Dezocine production process

-

Paragraph 0045; 0059; 0062, (2019/10/10)

The invention provides a dezocine production process, and relates to the technical field of medical chemistry. The dezocine production process comprises the following steps of 1) synthesis of dezocine ammonium salt, 2) synthesis of methyl dezocine salt, 3) synthesis of a crude dizocine product and 4) refining and packaging of the crude dizocine product. By means of the four processes of synthesis of dezocine ammonium salt, synthesis of methyl dezocine salt, synthesis of the crude dizocine product and refining and packaging of the crude dizocine product, the synthesis steps and the reaction conditions are optimized, the synthesis cycle is shortened, and meanwhile the detailed processes of the synthesis of dezocine ammonium salt, synthesis of methyl dezocine salt, synthesis of the crude dizocine product and refining of the crude dizocine product are described in details; key process parameters and product quality standards are defined, thus the dezocine production process can rapidly grasp key control points, and the synthesis reaction can be helped to be conducted efficiently and stably.

DEZOCINE ANALOGUE

-

Paragraph 0086; 0101; 0102, (2018/11/27)

Disclosed in the present invention is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.

Asymmetric alkylation of α-aryl substituted carbonyl compounds by means of chiral phase transfer catalysts. Applications for the synthesis of (+)-podocarp-8(14)-en-13-one and of (-)-Wy-16,225, a potent analgesic agent

Nerinckx,Vandewalle

, p. 265 - 276 (2007/10/02)

Asymmetric induction in the alkylation (alkyl halides and enones) of α-aryl substituted ketones, esters and lactones by means of CPTC has been evaluated. The catalysts used are the bromides of N-(p-trifluoromethyl) benzyl derivatives of cinchonine, cinchonidine, dihydrocinchonine and dihydrocinchonidine. The potential of the method is illustrated by the asymmetric synthesis of (+)-podocarp-8(14)-ene-13-one (13) and of (-)-Wy-16,225 (10), a bridged aminotetralin with potent analgesic properties.